𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Experimental tumor targeting with radiolabeled ligands

✍ Scribed by Donald J. Buchsbaum

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
134 KB
Volume
80
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Approaches have been developed in animal models to increase

πŸ“œ SIMILAR VOLUMES

Targeting cancer with radiolabeled antib
Targeting cancer with radiolabeled antibodies
✍ David M. Goldenberg; Steven M. Larson; Ralph A. Reisfeld; Jeffrey Schlom πŸ“‚ Article πŸ“… 1995 πŸ› Elsevier Science 🌐 English βš– 508 KB
Tumor targeting with radiolabeled antibo
Tumor targeting with radiolabeled antibodies in a human carcinoembryonic antigen transgenic mouse model
✍ GyΓΆrgy Szalai; Lawrence E. Williams; F. James Primus πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 French βš– 173 KB

Mice transgenic for the carcinoembryonic (CEA) gene were used to study the biodistribution and tumor targeting of a radioiodinated monoclonal antibody (MAb), T84.66. The specificity of antibody uptake in tumors was assessed in mice bearing a CEA-transfected syngeneic tumor as well as the antigen-neg

Ξ±vΞ²3 Integrin-targeting of intraperitone
Ξ±vΞ²3 Integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide
✍ Ingrid Dijkgraaf; John A.W. Kruijtzer; Cathelijne Frielink; Frans H.M. Corstens; πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 French βš– 134 KB

## Abstract Ovarian cancer is the fourth most common cause of cancer deaths among females in the western world after cancer of the breast, colon and lung. The inability to control the disease within the peritoneal cavity is the major cause of treatment failure in patients with ovarian cancer. The m

Targeting T cells against brain tumors w
Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate
✍ Edward J. Roy; Bryan K. Cho; Laurie A. Rund; Todd A. Patrick; David M. Kranz πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 French βš– 156 KB

High-affinity receptors expressed on the surface of some tumors can be exploited by chemically conjugating the ligand for the receptor and an antibody against immune effector cells, thus redirecting their cytolytic potential against the tumor. Ovarian carcinomas and some brain tumors express the hig